title: Common errors in multidrug-resistant tuberculosis management.
abstract: Multidrug-resistant tuberculosis (MDR-TB), defined as being resistant to at least rifampicin and isoniazid, has an increasing burden and threatens TB control. Diagnosis is limited and usually delayed while treatment is long lasting, toxic and poorly effective. MDR-TB management in scarce-resource settings is demanding however it is feasible and extremely necessary. In these settings, cure rates do not usually exceed 60-70% and MDR-TB management is novel for many TB programs. In this challenging scenario, both clinical and programmatic errors are likely to occur. The majority of these errors may be prevented or alleviated with appropriate and timely training in addition to uninterrupted procurement of high-quality drugs, updated national guidelines and laws and an overall improvement in management capacities. While new tools for diagnosis and shorter and less toxic treatment are not available in developing countries, MDR-TB management will remain complex in scarce resource settings. Focusing special attention on the common errors in diagnosis, regimen design and especially treatment delivery may benefit patients and programs with current outdated tools. The present article is a compilation of typical errors repeatedly observed by the authors in a wide range of countries during technical assistant missions and trainings.
authors: Tuberculosis and HIV Department, MDR-TB Unit, International Union against Tuberculosis and Lung Disease (The Union), París, France.
authors: Ignacio
authors: I
authors: Monedero
authors: Jose A
authors: JA
authors: Caminero
mesh_terms: D000284:Administration, Oral; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003906:Developing Countries; D003951:Diagnostic Errors / Q000517:prevention & control; D019468:Disease Management; D016503:Drug Delivery Systems / Q000009:adverse effects; D006801:Humans; D007267:Injections; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008508:Medication Errors / Q000517:prevention & control; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin